SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
Volume 309, Issue 9, Pages L1027-L1036
Publisher
American Physiological Society
Online
2015-09-12
DOI
10.1152/ajplung.00167.2015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
- (2015) William T. Cefalu et al. DIABETOLOGIA
- Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice
- (2015) Yusuke Kashiwagi et al. PLoS One
- Pulmonary Vascular Function in Insulin Resistance and Diabetes
- (2014) Javier Moral-Sanz et al. Current Vascular Pharmacology
- SGLT2 inhibitors in the treatment of type 2 diabetes
- (2014) Farhad M. Hasan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
- (2014) David Polidori et al. DIABETOLOGIA
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Impact of Diabetes on Survival and Right Ventricular Compensation in Pulmonary Arterial Hypertension
- (2014) Levi Benson et al. Pulmonary Circulation
- Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice
- (2013) Young-Eun Cho et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?
- (2013) Karen E. Porter et al. CLINICAL SCIENCE
- Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
- (2013) K. Tatarkiewicz et al. DIABETES OBESITY & METABOLISM
- Use of Inhaled Nitric Oxide in Preterm Infants
- (2013) Praveen Kumar et al. PEDIATRICS
- The vascular endothelium in diabetes—a therapeutic target?
- (2013) Kieren J. Mather REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Nitric Oxide Donor Agents for the Treatment of Ischemia/Reperfusion Injury in Human Subjects
- (2013) Brian W. Roberts et al. SHOCK
- Thyroid hormone receptor-α and vascular function
- (2012) Ayako Makino et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Improved glycemic control in mice lacking Sglt1 and Sglt2
- (2012) David R. Powell et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- STIM1 Restores Coronary Endothelial Function in Type 1 Diabetic Mice
- (2012) Irene A. Estrada et al. CIRCULATION RESEARCH
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- A novel SGLT is expressed in the human kidney
- (2012) Rajendra K. Kothinti et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
- (2012) Yin Liang et al. PLoS One
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter
- (2011) Rolf Grempler et al. FEBS LETTERS
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Cellular and molecular mechanisms of vascular injury in diabetes — Part II: Cellular mechanisms and therapeutic targets
- (2011) Rosalinda Madonna et al. VASCULAR PHARMACOLOGY
- Cellular and molecular mechanisms of vascular injury in diabetes — Part I: Pathways of vascular disease in diabetes
- (2011) Rosalinda Madonna et al. VASCULAR PHARMACOLOGY
- Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for New Anti-Diabetic Agent
- (2010) Sumihiro Nomura CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats
- (2010) F. R. Macdonald et al. DIABETES OBESITY & METABOLISM
- Glucose-Induced Regulation of NHEs Activity and SGLTs Expression Involves the PKA Signaling Pathway
- (2010) Olívia Beloto-Silva et al. JOURNAL OF MEMBRANE BIOLOGY
- SGLT2 inhibition — a novel strategy for diabetes treatment
- (2010) Edward C. Chao et al. NATURE REVIEWS DRUG DISCOVERY
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
- (2010) Jian Chen et al. Diabetes Therapy
- High glucose inhibits HCO 3 − and fluid secretion in rat pancreatic ducts
- (2009) Sachiko Futakuchi et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
- (2008) S. Han et al. DIABETES
- Recent developments in nitric oxide donor drugs
- (2007) M R Miller et al. BRITISH JOURNAL OF PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started